Earnings Call Summary | Theravance Biopharma(TBPH.US) Q1 2024 Earnings Conference
Earnings Call Summary | Theravance Biopharma(TBPH.US) Q1 2024 Earnings Conference
The following is a summary of the Theravance Biopharma, Inc. (TBPH) Q1 2024 Earnings Call Transcript:
以下是Theravance Biopharma, Inc.（TBPH）2024年第一季度财报电话会议记录摘要：
Financial Performance:
财务业绩：
Theravance Biopharma reported Q1 net sales of $55.2 million in partnership with Viatris, marking an 18% growth year-on-year.
The company ended the quarter with $100 million in cash and no debt, indicating a strong financial position.
The company is targeting a one-time sales milestone of $25 million from Viatris when YUPELRI net sales hit $250 million in a calendar year.
Theravance Biopharma报告称，与维亚特里斯合作的第一季度净销售额为5,520万美元，同比增长18％。
该公司在本季度末拥有1亿美元的现金，没有债务，这表明财务状况良好。
该公司的目标是将Viatris的一次性销售额提高到2500万美元，届时YUPELRI在一个日历年的净销售额达到2.5亿美元。
Business Progress:
业务进展：
YUPELRI, the company's main product, saw a significant 31% increase in hospital doses sold compared to the prior year.
Regulatory filing for YUPELRI in China is planned to be completed by Viatris by the middle of the year based on compelling Phase 3 results.
Completion of Phase 3 CYPRESS study for Ampreloxetine is projected to be achieved in the second half of the year.
The company anticipates YUPELRI to continue contributing significantly to business growth and value creation.
The company is focused on achieving potential milestones with its trilogy project, which may bolster its profitability.
Theravance expects a $7.5 million milestone payment upon the approval of the China equivalent of an NDA.
The company is upbeat about the Ampreloxetine data from CYPRESS and the results of the trilogy project, aiming to reach milestones that could amount to $200 million by 2026.
The company is planning to host an investor event on May 23rd to review all data on MSA, nOH, and Ampreloxetine and to discuss the company's opportunities and potential patient benefits.
该公司的主要产品YUPELRI的医院剂量与去年同期相比大幅增长了31％。
根据令人信服的第三阶段结果，Viatris计划在今年年中之前完成YUPELRI在中国的监管申请。
CYPRESS对安普洛西汀的第三阶段研究预计将在下半年完成。
该公司预计，YUPELRI将继续为业务增长和价值创造做出重大贡献。
该公司专注于通过其三部曲项目实现潜在的里程碑，这可能会提高其盈利能力。
Theravance预计，在中国批准相当于保密协议的协议后，将获得750万美元的里程碑式付款。
该公司对赛普拉斯的安普雷西汀数据和三部曲项目的结果持乐观态度，目标是到2026年达到可能达到2亿美元的里程碑。
该公司计划在5月23日举办一次投资者活动，审查有关MSA、NoH和Ampreloxetine的所有数据，并讨论该公司的机会和潜在的患者福利。
More details: Theravance Biopharma IR
更多详情： Theravance 生物制药红外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多详情，请访问投资者关系网站。本文仅供投资者参考，不构成任何投资建议。
译文内容由第三方软件翻译。